References
- Daly E, Vessey MP, Barlow D, Gray A, McPherson K, Roche M. Hormone replacement therapy in a risk—benefit perspective. Maturitas 1996;23:247–59
- Akkad A, Hartshorne T, Bell PR, Al-Azzawi F. Carotid plaque regression on oestrogen replace-ment: a pilot study. Eur J Vasc Endovasc Surg 1996;11:347–8
- Nabulsi AA, Folsom AR, White A, Patsch W, Weiss G, Wu KK. Association of hormone replacement therapy with various cardiovascular risk factors in postmenopausal women. The Atherosclerosis Risk in Communities Study Investigators. N Engl J Med 1993;328:1069–75
- Al-Azzawi F, Habiba M. Regular bleeding on hormone replacement therapy: a myth? Br J Obstet Gynaecol 1994;101:661–2
- Magos A, Brewster E, Singh R, O'Dowd T, Brincat M, Studd JW. The effects of norethis-terone in postmenopausal women on oestrogen replacement therapy: a model for the pre-menstrual syndrome. Br J Obstet Gynaecol 1986; 93:1290–6
- Nachtigall LE. Enhancing patient compliance with hormone replacement therapy at meno-pause. Obstet Gyneco/ 1990;75:77-805; discus-sion 81-3S
- Dören M, Schneider HP. Long-term compliance of continuous combined estrogen and progest-ogen replacement in postmenopausal women. Maturitas 1996;25:99–105
- Habiba MA, Bell SC, Abrams K, Al-Azzawi F. Endometrial responses to hormone replacement therapy: the bleeding pattern. Hum Reprod 1996;11:503–8
- Philibert D, Bouchoux F, Degryse M, et al. The pharmacological profile of a novel norpregnane progestin (trimegestone). Gynecol Endocrinol 1999;13:316–26
- Kupperman HS, Blatt MHG, Wiesbader H, Filler W. Comparative clinical evaluation of estrogenic preparations by the menopausal and amenorrheal indices. J Gun Endocrinol Metab 1953;13:688–703
- Patterson HD, Thompson R. Recovery of inter-block information when block sizes are unequal. Biometrika 1971;58:545–54
- Genstat. Genstat 5 Committee, GENSTAT 5 Release3 references manual. Oxford: Clarenden, 1993
- Harlow SD, Zeger SL. An application of longi-tudinal methods to the analysis of menstrual diary data. J Gun Epidemiol 1991;44:1015–25
- Dunnett CW, Gent M. Significance testing to establish equivalence between treatments, with special reference to data in the form of 2X2 tables. Biometrics 1977;33:593–602
- Fleiss JL. Statistical Methods for Rates and Proportions. New York: John Wiley and Sons Inc., 1981
- Al-Azzawi F, Wahab M, Thompson J, Whitehead M, Thompson W. Acceptability and patterns of uterine bleeding in sequential trimegestone-based hormone replacement therapy: a dose-ranging study. Hum Reprod 1999;14:636–41
- Ross D, Godfree V, Cooper A, Pryse-Davies J, Whitehead MI. Endometrial effects of three doses of trimegestone, a new orally active progestogen, on the postmenopausal endometrium. Maturitas 1997;28:83–8
- Wahab M, Thompson J, Al-Azzawi F. The effect of submucous fibroids on the dose-dependent modulation of uterine bleeding by trimegestone in postmenopausal women treated with hormone replacement therapy. Br J Obstet Gynaecol 2000; 107:329–34
- Mittsson LA, Cullberg G, Samsioe G. Evaluation of a continuous oestrogen—progestogen regimenfor climacteric complaints. Maturitas 1982;4: 95–102
- Staland B. Continuous treatment with natural oestrogens and progestogens. A method to avoid endometrial stimulation. Maturitas 1981;3: 145–56
- Wahab M, Thompson J, Al-Azzawi F. Effect of different cyclical sequential progestins on endo-metrial vascularity in postmenopausal women compared with the natural cycle: a morphometric analysis. Hum Reprod 2000;15:2075–81